HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardium Therapeutics Packages MedPodium Line For Impulse Shoppers

This article was originally published in The Tan Sheet

Executive Summary

The development stage health sciences and regenerative medicine company looks to the MedPodium line as its first revenue-generating products. Cardium packages the MedPodium line for consumers who prefer to buy smaller packages at a lower price point and often buy products on-the-go when they need them.

You may also be interested in...



P&G Launches ZzzQuil To Enter OTC Sleep Aid Category

While other national brand names compete in the OTC sleep aid tablet category, P&G’s NyQuil line extension is by far the biggest name among current players in the liquid product category, which has annual growth of nearly 80%.

Supplement Sales Will Slow, Bright Spots Are Brain Health And Energy

Supplement categories poised for growth include those that address specific health issues, such as brain, bone and immunity. Others include energy shots, sleep aids, organic supplements and other well-researched and supported products, stakeholders and analysts predict.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel